
President Obama meets with Kent Brantly and his wife, Amber, in the Oval Office on Sept. 16
Mapp Biopharmaceutical, the San Diego company that developed ZMapp, is also in a way a White House project. It's supported exclusively through federal grants and contracts that go back to 2005. The antibody mixture hadn't yet passed its first phase of human clinical trials, but after the two Americans were infected with Ebola, the Food and Drug Administration granted emergency access to ZMapp.
It's too early to say whether ZMapp was vital to the Americans' survival. There were a limited number of doses available. Mapp ran out after having given doses to the two Americans, a Spanish priest, and doctors in two West African countries, although it declined to say how many. And that raised fair questions: Why hadn't the promising treatment gone through human clinical trials sooner, and why were there so few doses on hand?














Comment: At the very least, the story of ZMapp demonstrates what the authors above allege: gross incompetence and wrong priorities. However, that is not the only possibility. First, we need to know if the drug is actually effective or not. If it is, was its development deliberately obstructed?